|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 271.00 USD | -0.30% |
|
-4.83% | -1.54% |
| 13/01 | Gilead's new HIV prevention shot added to CVS's drug coverage lists, CEO says | RE |
| 09/01 | Mizuho Securities Adjusts Cigna Group Price Target to $325 From $307, Maintains Outperform Rating | MT |
| Capitalization | 7.26TCr 6.23TCr 5.8TCr 5.4TCr 10TCr 6,55500Cr 11TCr 67TCr 26TCr 3,13600Cr 27TCr 27TCr 11,48900Cr | P/E ratio 2025 * |
11.3x | P/E ratio 2026 * | 10.9x |
|---|---|---|---|---|---|
| Enterprise value | 9.65TCr 8.28TCr 7.71TCr 7.18TCr 13TCr 8,71600Cr 14TCr 89TCr 35TCr 4,16900Cr 36TCr 35TCr 15,27800Cr | EV / Sales 2025 * |
0.36x | EV / Sales 2026 * | 0.32x |
| Free-Float |
69.07% | Yield 2025 * |
2.16% | Yield 2026 * | 2.24% |
Last Transcript: Cigna
| 1 day | -0.30% | ||
| 1 week | -4.83% | ||
| Current month | -1.54% | ||
| 1 month | -1.35% | ||
| 3 months | -8.26% | ||
| 6 months | -10.64% | ||
| Current year | -1.54% |
| 1 week | 270.31 |  | 286.88 |
| 1 month | 268.8 | | 289.03 |
| Current year | 270.31 | | 289.03 |
| 1 year | 239.51 | | 350 |
| 3 years | 239.51 | | 370.82 |
| 5 years | 191.74 | | 370.82 |
| 10 years | 115.03 | | 370.82 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Cordani
CEO | Chief Executive Officer | 60 | 01/12/2009 |
Ann Dennison
DFI | Director of Finance/CFO | 55 | 31/03/2025 |
Brian Evanko
DFI | Director of Finance/CFO | 49 | 01/01/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
David Cordani
CHM | Chairman | 60 | 01/01/2022 |
Eric Foss
BRD | Director/Board Member | 67 | 01/01/2011 |
| Director/Board Member | 66 | 01/01/2018 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | 0.00% | 2.33% | 5 M€ | |
| +1.23% | 2.28% | 26 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.30% | -4.83% | -4.05% | -13.75% | 7.26TCr | |
| +0.31% | -4.01% | -38.10% | -31.58% | 30TCr | |
| +0.58% | +0.40% | -5.96% | -22.81% | 8.24TCr | |
| +0.07% | -2.04% | -4.60% | -44.21% | 3.3TCr | |
| +0.90% | +0.94% | -27.52% | -40.07% | 2.25TCr | |
| +4.39% | +2.25% | -35.85% | -37.09% | 929.98Cr | |
| +3.94% | +2.09% | +61.07% | +73.13% | 418.59Cr | |
| +3.49% | -2.06% | +28.67% | -21.51% | 217.6Cr | |
| +10.63% | +8.49% | -24.46% | +126.61% | 131.24Cr | |
| -1.73% | -3.58% | -23.23% | - | 37Cr | |
| Average | +2.19% | -2.23% | -7.40% | -1.25% | 5.3TCr | |
| Weighted average by Cap. | +0.18% | -3.32% | -24.78% | -27.76% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 27TCr 23TCr 22TCr 20TCr 38TCr 24,42300Cr 40TCr 2,48500Cr 98TCr 11,68300Cr 1,01500Cr 99TCr 42,81000Cr | 28TCr 24TCr 23TCr 21TCr 39TCr 25,55100Cr 42TCr 2,60000Cr 1,02300Cr 12,22200Cr 1,06100Cr 1,04000Cr 44,78600Cr |
| Net income | 646.64Cr 554.88Cr 516.64Cr 480.78Cr 897.18Cr 58TCr 967.18Cr 5.94TCr 2.34TCr 28TCr 2.43TCr 2.38TCr 1,02300Cr | 650.38Cr 558.09Cr 519.63Cr 483.56Cr 902.37Cr 59TCr 972.77Cr 5.97TCr 2.35TCr 28TCr 2.44TCr 2.39TCr 1,02900Cr |
| Net Debt | 2.39TCr 2.05TCr 1.91TCr 1.78TCr 3.32TCr 2,16100Cr 3.58TCr 22TCr 8.65TCr 1,03400Cr 8.98TCr 8.79TCr 3,78800Cr | 1.87TCr 1.61TCr 1.5TCr 1.39TCr 2.6TCr 1,69200Cr 2.8TCr 17TCr 6.77TCr 81TCr 7.03TCr 6.88TCr 2,96500Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/26/14 | 271.00 $ | -0.30% | 18,20,855 |
| 13/26/13 | 271.81 $ | -1.53% | 10,14,254 |
| 12/26/12 | 276.02 $ | -1.05% | 16,16,634 |
| 09/26/09 | 278.95 $ | -1.75% | 16,96,447 |
| 08/26/08 | 283.91 $ | +1.72% | 13,98,780 |
Delayed Quote Nyse, January 15, 2026 at 02:30 am IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CI Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition